title: Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"?
authors.affiliation: Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis 68132, Greece. papanasnikos@yahoo.gr.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Papanas
authors.forename: Costas
authors.initials: C
authors.lastname: Tsioufis
authors.forename: Efstratios S
authors.initials: ES
authors.lastname: Maltezos
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000401:mortality*; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C570240:empagliflozin